Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | 10% owner | December 22, 2020 | December 23, 2020 |
| Boundless Bio, Inc.BOLD · Entity 7063 | 10% owner | July 01, 2026 | July 06, 2026 |
| Codiak BioSciences, Inc.CDAK · Entity 114958 | 10% owner | September 13, 2022 | September 15, 2022 |
| Denali Therapeutics Inc.DNI · Entity 1735 | 10% owner | August 08, 2019 | August 13, 2019 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | 10% owner | February 12, 2019 | February 12, 2019 |
| IMPINJ INCPI · Entity 3883 | Director | October 23, 2020 | October 23, 2020 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | 10% owner | March 06, 2026 | March 09, 2026 |
| Metacrine, Inc.MTCR · Entity 115177 | 10% owner | September 18, 2020 | September 22, 2020 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | 10% owner | October 27, 2025 | October 29, 2025 |
| Q32 Bio Inc.FIXX · Entity 5594 | 10% owner | May 21, 2019 | May 23, 2019 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | 10% owner | February 08, 2024 | February 12, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | May 29, 2018 | June 01, 2018 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | 10% owner | February 22, 2019 | February 26, 2019 |
| Twist Bioscience CorpTWST · Entity 3619 | 10% owner | November 02, 2018 | November 06, 2018 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | 10% owner | May 07, 2018 | May 07, 2018 |
| XTERA COMMUNICATIONS, INC.XCOM · Entity 181654 | Director · 10% owner | October 11, 2016 | October 13, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date December 22, 2020 · Filed December 23, 2020
Jointly reported with ARCH Venture Fund VII, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 5,725,045 |
Last balance in matching sequence
After 2020-12-22 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-12-22 · Conversion · Acquired 5,425,045 · Balance 5,425,045 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-22 · Purchase · Acquired 300,000 · Balance 5,725,045 F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-22 · Conversion · Disposed 2,927,386 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-22 · Conversion · Disposed 981,443 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-22 · Conversion · Disposed 669,977 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-22 · Conversion · Disposed 665,661 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-22 · Conversion · Disposed 180,578 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Boundless Bio, Inc.
Report date July 01, 2026 · Filed July 06, 2026
Jointly reported with CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, Burow Kristina
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Last balance in matching sequence
After 2026-07-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-01 · Exercise / conversion · Acquired 16,000 · Balance 16,000 F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. Row 2 · 2026-07-01 · Sale · Disposed 16,000 · Balance 0 F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-06-22 | IndirectSee footnote | 0 |
Reported balance
After 2026-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-01 · Exercise / conversion · Disposed 16,000 · Balance 0 F7: The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders. F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 683,759 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 683,759 F2: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 828,570 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 828,570 F3: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,181,766 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,181,766 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Kristina Burow, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer.
F2: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F3: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Kristina Burow, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F7: The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders.
Codiak BioSciences, Inc.
Report date September 13, 2022 · Filed September 15, 2022
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SotckSEC Table I · non-derivative | IndirectSee footnotes | 8,854,098 |
Reported balance
After 2022-09-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-09-13 · Purchase · Acquired 5,000,000 · Balance 8,854,098 F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share. F2: Comprised of 7,503,903 shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") and 1,350,195 shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. F4: Shares held by ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-09-13 | Direct | 5,000,000 |
Reported balance
After 2022-09-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-13 · Purchase · Acquired 5,000,000 · Balance 5,000,000 F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share. F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
F2: Comprised of 7,503,903 shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") and 1,350,195 shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage").
F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
F4: Shares held by ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Denali Therapeutics Inc.
Report date August 08, 2019 · Filed August 13, 2019
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Partners VIII, L.P., ARCH Venture Partners VIII, LLC, CRANDELL KEITH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,668,749 |
Reported balance
After 2019-08-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-08-08 · Other · Disposed 400,000 · Balance 10,668,749 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: Following the transactions reported herein, 10,668,749 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell and Clinton Bybee are managing directors of ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: Following the transactions reported herein, 10,668,749 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").
F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell and Clinton Bybee are managing directors of ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Gossamer Bio, Inc.
Report date February 12, 2019 · Filed February 12, 2019
Jointly reported with ARCH Venture Partners IX, LLC, ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Partners IX, L.P., NELSEN ROBERT, CRANDELL KEITH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,682,539 |
Reported balance
After 2019-02-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-02-12 · Conversion · Acquired 3,682,539 · Balance 3,682,539 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,027,958 |
Reported balance
After 2019-02-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-02-12 · Conversion · Acquired 345,419 · Balance 4,027,958 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,682,539 |
Reported balance
After 2019-02-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-02-12 · Conversion · Acquired 3,682,539 · Balance 3,682,539 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,027,958 |
Reported balance
After 2019-02-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2019-02-12 · Conversion · Acquired 345,419 · Balance 4,027,958 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-12 · Conversion · Disposed 16,571,429 · Balance 0 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-12 · Conversion · Disposed 16,571,428 · Balance 0 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-12 · Conversion · Disposed 1,554,388 · Balance 0 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-12 · Conversion · Disposed 1,554,388 · Balance 0 F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC.
F3: Each of GPLP, ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC.
IMPINJ INC
Report date October 23, 2020 · Filed October 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,125 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Exercise / conversion · Acquired 3,411 · Balance 17,125 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-23 · Exercise / conversion · Disposed 3,411 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Impinj common stock. F2: On October 23, 2019, the reporting person was granted 3,411 RSUs. These RSUs fully vested on October 23, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Impinj common stock.
F2: On October 23, 2019, the reporting person was granted 3,411 RSUs. These RSUs fully vested on October 23, 2020.
Lyell Immunopharma, Inc.
Report date March 06, 2026 · Filed March 09, 2026
Jointly reported with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BERNS PAUL L
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,426,528 |
Reported balance
After 2026-03-06 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-03-06 · Purchase · Acquired 488,090 · Balance 1,426,528 F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 910,317 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 910,317 F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 910,317 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 910,317 F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
Metacrine, Inc.
Report date September 18, 2020 · Filed September 22, 2020
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,960,784 |
Reported balance
After 2020-09-18 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-09-18 · Conversion · Acquired 1,960,784 · Balance 1,960,784 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,433,035 |
Reported balance
After 2020-09-18 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-09-18 · Conversion · Acquired 472,251 · Balance 2,433,035 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,571,769 |
Reported balance
After 2020-09-18 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-09-18 · Conversion · Acquired 138,734 · Balance 2,571,769 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,781,769 |
Reported balance
After 2020-09-18 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-09-18 · Purchase · Acquired 210,000 · Balance 2,781,769 F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 138,734 |
Reported balance
After 2020-09-18 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-09-18 · Conversion · Acquired 138,734 · Balance 138,734 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 158,734 |
Reported balance
After 2020-09-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-09-18 · Purchase · Acquired 20,000 · Balance 158,734 F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-18 · Conversion · Disposed 1,960,784 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-18 · Conversion · Disposed 472,251 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-09-18 · Conversion · Disposed 138,734 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-09-18 · Conversion · Disposed 138,734 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Neumora Therapeutics, Inc.
Report date October 27, 2025 · Filed October 29, 2025
Jointly reported with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 6,046,907 |
Reported balance
After 2025-10-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-10-27 · Purchase · Acquired 1,915,700 · Balance 6,046,907 F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VII, L.P. | 1,387,228 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,387,228 F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VIII Overage, L.P. | 2,321,566 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,321,566 F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X, L.P. | 12,205,379 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 12,205,379 F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X Overage, L.P. | 11,886,758 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,886,758 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
Q32 Bio Inc.
Report date May 21, 2019 · Filed May 23, 2019
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VIII, L.P., ARCH Venture Partners VIII, LLC, CRANDELL KEITH, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,768,694 |
Reported balance
After 2019-05-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-05-21 · Other · Disposed 300,001 · Balance 5,768,694 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: Following the transactions reported herein, includes 1,137,663 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,631,031 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: Following the transactions reported herein, includes 1,137,663 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,631,031 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").
F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Sana Biotechnology, Inc.
Report date February 08, 2024 · Filed February 12, 2024
Jointly reported with CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,667,387 |
Reported balance
After 2024-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-02-08 · Purchase · Acquired 363,637 · Balance 10,667,387 F1: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,446,022 |
Reported balance
After 2024-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2024-02-08 · Purchase · Acquired 727,272 · Balance 12,446,022 F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,446,022 |
Reported balance
After 2024-02-08 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2024-02-08 · Purchase · Acquired 727,272 · Balance 12,446,022 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,301,250 |
Reported balance
Holding disclosure · report date 2024-02-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,301,250 F2: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F2: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
Scholar Rock Holding Corp
Report date May 29, 2018 · Filed June 01, 2018
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Partners VIII, LLC, CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VIII, L.P. | 2,637,617 |
Last balance in matching sequence
After 2018-05-29 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2018-05-29 · Conversion · Acquired 437,859 · Balance 437,859 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 2 · 2018-05-29 · Conversion · Acquired 634,579 · Balance 1,072,438 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 3 · 2018-05-29 · Conversion · Acquired 551,807 · Balance 1,624,245 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 4 · 2018-05-29 · Conversion · Acquired 719,559 · Balance 2,343,804 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 5 · 2018-05-29 · Conversion · Acquired 293,813 · Balance 2,637,617 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-2 PreferredSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund VIII, L.P. | 0 |
Reported balance
After 2018-05-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-29 · Conversion · Disposed 1,249,999 · Balance 0 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-3 PreferredSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund VIII, L.P. | 0 |
Reported balance
After 2018-05-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-29 · Conversion · Disposed 1,811,595 · Balance 0 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-4 PreferredSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund VIII, L.P. | 0 |
Reported balance
After 2018-05-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-29 · Conversion · Disposed 1,575,299 · Balance 0 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B PreferredSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund VIII, L.P. | 0 |
Reported balance
After 2018-05-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-29 · Conversion · Disposed 2,054,197 · Balance 0 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C PreferredSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund VIII, L.P. | 0 |
Reported balance
After 2018-05-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-29 · Conversion · Disposed 838,780 · Balance 0 F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date.
F2: The reportable securities are owned directly by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Sienna Biopharmaceuticals, Inc.
Report date February 22, 2019 · Filed February 26, 2019
Jointly reported with ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VIII, L.P., CRANDELL KEITH, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,900,575 |
Reported balance
After 2019-02-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-02-22 · Purchase · Acquired 150,000 · Balance 2,900,575 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,032,493 |
Reported balance
After 2019-02-22 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-02-22 · Purchase · Acquired 150,000 · Balance 1,032,493 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,865,800 |
Reported balance
After 2019-02-22 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-02-22 · Purchase · Acquired 1,865,800 · Balance 1,865,800 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F3: The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage").
F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Twist Bioscience Corp
Report date November 02, 2018 · Filed November 06, 2018
Jointly reported with ARCH Venture Partners VIII, LLC, ARCH Venture Fund VII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,182,645 |
Reported balance
After 2018-11-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-02 · Conversion · Acquired 1,182,645 · Balance 1,182,645 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,900,920 |
Reported balance
After 2018-11-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-02 · Conversion · Acquired 718,275 · Balance 1,900,920 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,167,696 |
Reported balance
After 2018-11-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-02 · Conversion · Acquired 266,776 · Balance 2,167,696 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,392,422 |
Reported balance
After 2018-11-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-11-02 · Conversion · Acquired 224,726 · Balance 2,392,422 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,407,422 |
Reported balance
After 2018-11-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-11-02 · Purchase · Acquired 15,000 · Balance 2,407,422 F4: Reflects shares purchased in the Issuer's initial public offering. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 894,146 |
Reported balance
After 2018-11-02 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-11-02 · Conversion · Acquired 894,146 · Balance 894,146 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 954,146 |
Reported balance
After 2018-11-02 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-02 · Purchase · Acquired 60,000 · Balance 954,146 F4: Reflects shares purchased in the Issuer's initial public offering. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-11-02 · Conversion · Disposed 1,182,645 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-11-02 · Conversion · Disposed 718,275 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-11-02 · Conversion · Disposed 266,776 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-11-02 · Conversion · Disposed 224,726 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-11-02 · Conversion · Disposed 894,146 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: Reflects shares purchased in the Issuer's initial public offering.
F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F6: The expiration date is not relevant to the conversion of these securities.
Unity Biotechnology, Inc.
Report date May 07, 2018 · Filed May 07, 2018
Jointly reported with ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,070,172 |
Reported balance
After 2018-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-07 · Conversion · Acquired 2,030,625 · Balance 2,070,172 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,298,604 |
Reported balance
After 2018-05-07 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-07 · Conversion · Acquired 4,228,432 · Balance 6,298,604 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,365,764 |
Reported balance
After 2018-05-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-05-07 · Conversion · Acquired 2,067,160 · Balance 8,365,764 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,486,745 |
Reported balance
After 2018-05-07 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-05-07 · Conversion · Acquired 1,486,745 · Balance 1,486,745 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,682,417 |
Reported balance
After 2018-05-07 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-05-07 · Conversion · Acquired 195,672 · Balance 1,682,417 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-07 · Conversion · Disposed 2,030,625 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-07 · Conversion · Disposed 4,228,432 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-07 · Conversion · Disposed 2,067,160 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-07 · Conversion · Disposed 1,486,745 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-07 · Conversion · Disposed 195,672 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2: The expiration date is not relevant to the conversion of these securities.
F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
XTERA COMMUNICATIONS, INC.
Report date October 11, 2016 · Filed October 13, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2026-10-11 | IndirectSee Footnote | 500,167 |
Reported balance
After 2016-10-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-11 · Purchase · Acquired 83,500 · Balance 500,167 F1: The Warrants reported on this Form 4 were issued by Xtera Communications, Inc. (the "Company") as part of a private placement of secured promissory notes (the "Notes"). Each purchaser of Notes received warrants to purchase one share of the Company's Common Stock for each $1.00 of principal amount of Notes purchased F2: The Warrants are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VI LLC are Clinton Bybee, Keith Crandell and Robert Nelsen, and as such they may be deemed to have shared voting and investment power over the shares held by ARCH Fund VI. Mr. Bybee is a member of the Company's board of directors. Messrs. Bybee, Crandell and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Warrants reported on this Form 4 were issued by Xtera Communications, Inc. (the "Company") as part of a private placement of secured promissory notes (the "Notes"). Each purchaser of Notes received warrants to purchase one share of the Company's Common Stock for each $1.00 of principal amount of Notes purchased
F2: The Warrants are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VI LLC are Clinton Bybee, Keith Crandell and Robert Nelsen, and as such they may be deemed to have shared voting and investment power over the shares held by ARCH Fund VI. Mr. Bybee is a member of the Company's board of directors. Messrs. Bybee, Crandell and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Beam Therapeutics Inc.
Report date June 30, 2021 · Filed July 02, 2021
Jointly reported with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, NELSEN ROBERT
Section 16 reporting ended · disclosed 2021-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,921,520 |
Reported balance
After 2021-06-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-30 · Other · Disposed 200,000 · Balance 2,921,520 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,921,519 |
Reported balance
After 2021-06-30 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-06-30 · Other · Disposed 200,000 · Balance 2,921,519 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 15,328 |
Reported balance
After 2021-06-30 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-06-30 · Other · Acquired 2,555 · Balance 15,328 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares held directly by Crandell. |
| Common StockSEC Table I · non-derivative | Direct | 4,867 |
Reported balance
After 2021-06-30 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-06-30 · Other · Acquired 811 · Balance 4,867 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares held directly by Bybee. |
| Common StockSEC Table I · non-derivative | Direct | 28,111 |
Reported balance
After 2021-06-30 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-06-30 · Other · Acquired 4,686 · Balance 28,111 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7: Shares held directly by Nelsen. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5: Shares held directly by Crandell.
F6: Shares held directly by Bybee.
F7: Shares held directly by Nelsen.
Karuna Therapeutics, Inc.
Report date April 13, 2021 · Filed April 15, 2021
Jointly reported with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH
Section 16 reporting ended · disclosed 2021-04-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,456,437 |
Reported balance
After 2021-04-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-04-13 · Other · Disposed 75,000 · Balance 1,456,437 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,456,435 |
Reported balance
After 2021-04-13 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-04-13 · Other · Disposed 75,000 · Balance 1,456,435 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 2,874 |
Reported balance
After 2021-04-13 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-04-13 · Other · Acquired 958 · Balance 2,874 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares held directly by Crandell. |
| Common StockSEC Table I · non-derivative | Direct | 918 |
Reported balance
After 2021-04-13 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-04-13 · Other · Acquired 306 · Balance 918 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares held directly by Bybee. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5: Shares held directly by Crandell.
F6: Shares held directly by Bybee.
Pulmatrix, Inc.
Report date April 03, 2018 · Filed April 12, 2018
Jointly reported with ARCH Venture Fund VII, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, CRANDELL KEITH, NELSEN ROBERT
Section 16 reporting ended · disclosed 2018-04-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Quanterix Corp
Report date November 20, 2020 · Filed November 24, 2020
Jointly reported with ARCH VENTURE FUND VI LP, ARCH Venture Fund VIII Overage, L.P., ARCH VENTURE PARTNERS VI LP, ARCH VENTURE PARTNERS VI LLC, ARCH Venture Partners VIII, LLC, NELSEN ROBERT
Section 16 reporting ended · disclosed 2020-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,182,995 |
Reported balance
After 2020-11-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-20 · Other · Disposed 229,006 · Balance 2,182,995 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,391,690 |
Reported balance
After 2020-11-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-11-20 · Other · Disposed 145,994 · Balance 1,391,690 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,905,481 |
Reported balance
After 2020-11-24 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-11-24 · Other · Disposed 277,514 · Balance 1,905,481 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,214,770 |
Reported balance
After 2020-11-24 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-11-24 · Other · Disposed 176,920 · Balance 1,214,770 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 854 |
Reported balance
After 2020-11-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-11-20 · Other · Acquired 854 · Balance 854 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares owned by Nelsen. |
| Common StockSEC Table I · non-derivative | Direct | 853 |
Reported balance
After 2020-11-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-11-20 · Other · Acquired 853 · Balance 853 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares owned by Bybee. |
| Common StockSEC Table I · non-derivative | Direct | 1,888 |
Reported balance
After 2020-11-24 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2020-11-24 · Other · Acquired 1,034 · Balance 1,888 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares owned by Nelsen. |
| Common StockSEC Table I · non-derivative | Direct | 1,889 |
Reported balance
After 2020-11-24 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2020-11-24 · Other · Acquired 1,036 · Balance 1,889 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares owned by Bybee. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5: Shares owned by Nelsen.
F6: Shares owned by Bybee.
Syros Pharmaceuticals, Inc.
Report date July 15, 2019 · Filed July 17, 2019
Jointly reported with ARCH Venture Fund VII, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, CRANDELL KEITH, NELSEN ROBERT
Section 16 reporting ended · disclosed 2019-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,302,051 |
Reported balance
After 2019-07-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-07-15 · Sale · Disposed 2,700 · Balance 4,302,051 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 4,276,572 |
Reported balance
After 2019-07-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-07-16 · Sale · Disposed 25,779 · Balance 4,276,572 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 4,242,051 |
Reported balance
After 2019-07-17 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-07-17 · Sale · Disposed 34,521 · Balance 4,242,051 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive.
F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Vir Biotechnology, Inc.
Report date September 02, 2022 · Filed September 08, 2022
Jointly reported with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH
Section 16 reporting ended · disclosed 2022-09-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,865,567 |
Reported balance
After 2022-09-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-09-02 · Other · Disposed 196,003 · Balance 5,865,567 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,601,096 |
Reported balance
After 2022-09-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-09-02 · Other · Disposed 253,997 · Balance 7,601,096 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 57,912 |
Reported balance
After 2022-09-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-09-02 · Other · Acquired 2,662 · Balance 57,912 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7: Shares held by a trust for the benefit of family members of Bybee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,626,008 |
Reported balance
After 2022-09-06 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2022-09-06 · Other · Disposed 239,559 · Balance 5,626,008 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,290,655 |
Reported balance
After 2022-09-06 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2022-09-06 · Other · Disposed 310,441 · Balance 7,290,655 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 61,160 |
Reported balance
After 2022-09-06 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2022-09-06 · Other · Acquired 3,248 · Balance 61,160 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7: Shares held by a trust for the benefit of family members of Bybee. |
| Common StockSEC Table I · non-derivative | Direct | 258,581 |
Reported balance
After 2022-09-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-09-02 · Other · Acquired 11,763 · Balance 258,581 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares held directly by Crandell. |
| Common StockSEC Table I · non-derivative | Direct | 28,946 |
Reported balance
After 2022-09-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-09-02 · Other · Acquired 1,338 · Balance 28,946 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares held directly by Bybee. |
| Common StockSEC Table I · non-derivative | Direct | 272,964 |
Reported balance
After 2022-09-06 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2022-09-06 · Other · Acquired 14,383 · Balance 272,964 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares held directly by Crandell. |
| Common StockSEC Table I · non-derivative | Direct | 30,570 |
Reported balance
After 2022-09-06 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2022-09-06 · Other · Acquired 1,624 · Balance 30,570 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares held directly by Bybee. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5: Shares held directly by Crandell.
F6: Shares held directly by Bybee.
F7: Shares held by a trust for the benefit of family members of Bybee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2022 Filed Sep 1, 2022 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018984 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 52,298 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018984 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,133 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018984 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,742 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018984 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,137,312 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018984 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,279,351 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 10 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 49,346 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 9 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,658 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 8 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,666 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 7 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,419,531 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 6 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,497,132 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 46,394 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,183 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,590 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,701,750 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018811 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,714,913 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018573 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,442 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018573 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,708 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018573 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,514 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018573 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,983,969 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018573 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,932,694 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 15 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 40,490 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 14 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,233 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 13 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,438 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 12 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,266,188 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 11 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,150,475 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 10 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,538 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 9 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,758 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 8 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,362 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 7 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,548,407 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 6 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,368,256 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,586 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Shares held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Shares held by a trust for the benefit of family members of Bybee. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,283 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,286 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,830,626 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-018154 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,586,037 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014696 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,634 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F7 · balance_after: Reclassified shares previously reported as direct to indirect to reflect these shares are held by a trust for the benefit of family members of Bybee. F7 · ownership.nature: Reclassified shares previously reported as direct to indirect to reflect these shares are held by a trust for the benefit of family members of Bybee. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014696 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,808 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · balance_after: Reclassified shares previously reported as direct to indirect to reflect these shares are held by a trust for the benefit of family members of Bybee. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014696 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,210 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014696 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,112,845 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014696 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,803,818 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 4,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014426 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,015 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014426 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,134 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014426 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,395,064 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014426 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,021,599 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 15,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,589 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 45,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,058 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 987,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,677,283 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 762,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,239,380 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 4,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,085 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 13,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,355 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.